{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/conjunctivitis-allergic/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"ba5e8d6b-90f7-5b69-b09a-2bb0c2692918","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field b84e8282-54f1-4ed8-abc5-e2788348fe10 --><h2>Update</h2><!-- end field b84e8282-54f1-4ed8-abc5-e2788348fe10 -->","summary":null,"htmlStringContent":"<!-- begin item f5621d83-76a6-4301-814c-1421b2748576 --><!-- end item f5621d83-76a6-4301-814c-1421b2748576 -->","topic":{"id":"b4698c45-6b7c-5244-836f-430591327957","topicId":"27f540e5-bb8e-4cee-a0aa-be515efa4fc2","topicName":"Conjunctivitis - allergic","slug":"conjunctivitis-allergic","lastRevised":"Last revised in October 2020","chapters":[{"id":"bc756208-c2a7-5b33-a4cb-67c41a75ecb0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6470bf56-596c-5d66-b2b2-ba79590bb255","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"17755f2a-0980-50f9-b62e-a34968c9682e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b1dc6613-43b4-55fe-9216-a83aab0ef918","slug":"changes","fullItemName":"Changes"},{"id":"ba5e8d6b-90f7-5b69-b09a-2bb0c2692918","slug":"update","fullItemName":"Update"}]},{"id":"fee1ca82-9d2a-50a4-9230-1a93482b8b4f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3d036930-da50-5ea2-82e1-1d0fb936a8b4","slug":"goals","fullItemName":"Goals"},{"id":"9ba6a0ce-0eae-5442-85f0-81f7ff71345b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"48935dfe-bca1-53fa-8d50-fa978331bd56","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"35b962f0-ec6b-53c9-b6f2-a5783ae10716","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8e9984f4-8c0d-5231-9eec-91a9fb49ecc4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8fa3b231-6e2b-5fa2-aa0c-eb5359ff8160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ebf46a5d-2a79-5df8-82dd-d23fcb0559f1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"67185462-9d0a-5b7d-b8af-80b8958f2420","slug":"definition","fullItemName":"Definition"},{"id":"1c320f1a-b91f-5d5b-a47b-dc0094518883","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b21baf96-f39b-5eeb-934b-c193a434933d","slug":"causes","fullItemName":"Causes"},{"id":"923b6415-5fe1-550a-baf5-89285f8ddf77","slug":"complications","fullItemName":"Complications"},{"id":"a679bff6-4749-539e-bdb0-a762a9f91728","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a7d99d63-f47f-54bf-a60f-8ae6f2a42fb9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"089d5cf7-0f6b-521b-88c1-d4f25eef7101","slug":"assessment","fullItemName":"Assessment"},{"id":"7bb8bdb4-0279-5783-ba21-e44e8bcd0832","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"9a95dbd6-aaa4-5d6a-aa5b-9635d279f9a0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"51e7c1d5-cd3d-5dea-a8ec-5a38deb58245","fullItemName":"Management","slug":"management","subChapters":[{"id":"e4ced49a-4b06-5559-9efb-c708812a8065","slug":"referral","fullItemName":"Scenario: Referral"},{"id":"77a507ec-4dff-5204-b375-121264b0adf8","slug":"management-in-primary-care","fullItemName":"Scenario: Management in primary care"}]},{"id":"452bc42e-1fe8-56e6-8511-57362d05fe3f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f9e89c16-d4a7-5241-86f6-1f78eacc68fa","slug":"topical-ocular-antihistamines-mast-cell-stabilizers","fullItemName":"Topical ocular antihistamines and mast cell stabilizers"},{"id":"f9a1678c-7117-5852-af35-628b676780c8","slug":"mast-cell-stabilizers","fullItemName":"Mast cell stabilizers"}]},{"id":"a32b7db8-1764-58b8-adbb-ab8ce0f44e46","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bd1a2d20-e91f-51f1-a2a2-486ebf015f65","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bc4e76de-c203-5f3e-ad9a-b84d6bc9d81e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"565b3a01-b21e-5837-b9f1-49fda55982ad","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b08973ef-af46-5e6f-b85c-d0bd9ca40bab","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3003e52e-8597-505e-a3ce-e46fde4c0c20","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b7947929-e2f9-50c7-b5cd-3e34b802bae1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3819cbbb-ca8c-58b7-b608-0a9567c5d5b5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"17755f2a-0980-50f9-b62e-a34968c9682e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"f5e380a7-923f-5119-89d0-a36730e5a13b","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field e88a23ef-a2c8-44b8-9378-2f5b16b85f4b --><h3>New evidence</h3><!-- end field e88a23ef-a2c8-44b8-9378-2f5b16b85f4b -->","summary":null,"htmlStringContent":"<!-- begin item d724e3fd-bd23-46bb-8edc-6ee6820865c2 --><!-- begin field 83972b6e-706e-4b30-86ad-6ffa610e7982 --><h3>Evidence-based guidelines</h3><!-- end field 83972b6e-706e-4b30-86ad-6ffa610e7982 --><!-- begin field f5e232ca-82ab-4f9e-8f2d-f7b57681b214 --><p>No new evidence-based guidelines since 1 May 2017.</p><!-- end field f5e232ca-82ab-4f9e-8f2d-f7b57681b214 --><!-- begin field 271d6fc1-f48d-464a-a93d-730895481377 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 271d6fc1-f48d-464a-a93d-730895481377 --><!-- begin field c46501b8-e965-406d-aa20-add6fcf6db10 --><p>No new HTAs since 1 May 2017.</p><!-- end field c46501b8-e965-406d-aa20-add6fcf6db10 --><!-- begin field 6fe5b6d7-7446-4e16-b075-7bca97e0b2cc --><h3>Economic appraisals</h3><!-- end field 6fe5b6d7-7446-4e16-b075-7bca97e0b2cc --><!-- begin field 5bcd5f9f-7cc2-4d71-b255-85e538667c91 --><p>No new economic appraisals relevant to England since 1 May 2017.</p><!-- end field 5bcd5f9f-7cc2-4d71-b255-85e538667c91 --><!-- begin field ff927a0a-9264-4aa6-81d7-e7cc3e209c13 --><h3>Systematic reviews and meta-analyses</h3><!-- end field ff927a0a-9264-4aa6-81d7-e7cc3e209c13 --><!-- begin field 3784865f-834a-40af-9e96-5ac1a68aec4b --><p>No new systematic reviews published since 1 May 2017.</p><!-- end field 3784865f-834a-40af-9e96-5ac1a68aec4b --><!-- begin field a91fad86-b8b4-4751-97a5-de56e849de07 --><h3>Primary evidence</h3><!-- end field a91fad86-b8b4-4751-97a5-de56e849de07 --><!-- begin field 54850573-260b-467f-9ca6-7caaf9c3be7e --><p>No new randomized controlled trials in the major journals since 1 May 2017.</p><!-- end field 54850573-260b-467f-9ca6-7caaf9c3be7e --><!-- end item d724e3fd-bd23-46bb-8edc-6ee6820865c2 -->","subChapters":[]},{"id":"b04271ba-8277-5df5-9857-51e5d16d828d","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 4ed661c3-5aa9-4112-9572-988cb518f811 --><h3>New policies</h3><!-- end field 4ed661c3-5aa9-4112-9572-988cb518f811 -->","summary":null,"htmlStringContent":"<!-- begin item 45344e8c-1593-485d-969b-4ee44227c9db --><!-- begin field 56f36ae5-0640-49a5-8182-616bfccb5c56 --><p>No new national policies or guidelines since 1 May 2017.</p><!-- end field 56f36ae5-0640-49a5-8182-616bfccb5c56 --><!-- end item 45344e8c-1593-485d-969b-4ee44227c9db -->","subChapters":[]},{"id":"30e1e174-92a4-5c6a-baa7-49ee6d869f14","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field a11d11e6-672f-46f2-8f32-8bd34fa62376 --><h3>New safety alerts</h3><!-- end field a11d11e6-672f-46f2-8f32-8bd34fa62376 -->","summary":null,"htmlStringContent":"<!-- begin item e81978e4-75a6-4c9f-89a2-d3e6e7d93518 --><!-- begin field c05c740c-64b7-48c9-adc7-42470e8a72a8 --><p>No new safety alerts since 1 May 2017.</p><!-- end field c05c740c-64b7-48c9-adc7-42470e8a72a8 --><!-- end item e81978e4-75a6-4c9f-89a2-d3e6e7d93518 -->","subChapters":[]},{"id":"9f381de9-c52c-5071-ae22-dfe30db96bb5","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 4a8cbcd0-ab72-4ee1-8edd-2f16f5fda06d --><h3>Changes in product availability</h3><!-- end field 4a8cbcd0-ab72-4ee1-8edd-2f16f5fda06d -->","summary":null,"htmlStringContent":"<!-- begin item d4cc447b-2067-4538-a8f1-aa1ba75c07be --><!-- begin field 986f02c1-f802-44fe-bb3f-63cf368266e2 --><ul><li>Bilastine 10 mg orodispersible tablets are non-sedating, long-acting histamine antagonist with selective peripheral H1 receptor antagonist affinity are licensed for use in children aged 6 to 11 years with body weight ≥20 kg for symptomatic treatment of allergic rhino-conjunctivitis (seasonal, perennial) and urticaria. See more <a href=\"https://www.medicines.org.uk/emc/product/11727/smpc\" data-hyperlink-id=\"d9deb3b7-150f-48f5-a98a-ac4f00a78d5a\">here</a>.</li></ul><!-- end field 986f02c1-f802-44fe-bb3f-63cf368266e2 --><!-- end item d4cc447b-2067-4538-a8f1-aa1ba75c07be -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}